The global vaccine market 2024-2025

According to the WHO Global Vaccine Market Report 2024 and supporting financial data from major pharmaceutical rankings and peer-reviewed analyses, the following twelve companies accounted for the most global human vaccine doses sold and vaccine revenue in 2024.  Please note that India and China are already listed here, and we expect them to increase their shares rapidly. Rank(by doses sold) Company Country HQ Estimated Doses Sold (billion) 2024 Vaccine Revenue (USD billions) Key Vaccine Portfolio 1 Serum Institute of India (SII) India ~2.8 2.5 MMR, MR, PCV10 (Pneumosil), HPV, DTP, MenA 2 Pfizer Inc. USA ~2.5 11.9 Pneumococcal (Prevnar), RSV (Abrysvo), COVID-19 (Comirnaty) 3 GSK plc United Kingdom ~1.6 9.8 Shingrix, Synflorix, MenACWY, Hepatitis A/B 4 Merck & Co., Inc. (MSD) USA ~1.3 12.1 HPV (Gardasil 9), MMR II, Varivax, RotaTeq 5 Sanofi SA France ~1.1 7.2 Influenza (Vaxigrip), Menactra, Pentaxim, Tdap 6 Moderna Inc. USA ~0.9 6.5 COVID-19 (Spikevax), RSV, cytomegalovirus candidates 7 CNBG (Sinopharm Group) China ~0.8 2.6 COVID-19, Hepatitis B, EV71, Rotavirus 8 CSL Seqirus Australia ~0.4 2.1 Seasonal/adjuvanted influenza, COVID boosters 9 Bavarian Nordic A/S Denmark ~0.2 1.0 Mpox/Smallpox (Imvanex/Jynneos), Rabipur, Encepur 10 Bharat Biotech India ~0.2 0.7 Rotavac, Covaxin, Typbar TCV 11 Beijing Wantai Biological Pharmacy China ~0.15 0.4 HPV (bivalent), Hepatitis E, Influenza 12 Bio Farma (Indonesia) Indonesia ~0.1 0.3 DTP, Polio, Measles, locally produced MR Additional insights (WHO 2024): The top ten companies...